Skip to main content

Market Overview

United Therapeutics Pulls Plug On Trevyent Development


Based on the FDA’s written comments, United Therapeutics Corporation (NASDAQ: UTHR) has decided to discontinue the development of Trevyent.

  • Trevyent is a drug-device combination product that combines two-day, single-use, disposable PatchPump technology with treprostinil for the subcutaneous treatment of pulmonary arterial hypertension.
  • The comments followed a meeting to discuss the company’s planned resubmission of its marketing application for Trevyent in light of a Complete Response Letter issued in April last year.
  • The FDA’s comments indicated that United Therapeutics would need to redesign the product to improve pump accuracy in certain respects and conduct a clinical study of the redesigned product.
  • Thus, the company will stop the development of Trevyent as it is no longer considered commercially reasonable.
  • Initially, the company submitted Trevyent application in September 2019.
  • The company expects to incur an impairment charge of roughly $107.3 million during the first quarter of 2021.
  • Price Action: UTHR shares are down 0.35% at $166 in premarket trading on the last check Wednesday.

Related Articles (UTHR)

View Comments and Join the Discussion!

Posted-In: Phase 3Biotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at